Hearing loss is one of the most common sensory impairments, affecting a large number of people. According to the World Hearing Report, more than 1.5 billion people currently suffer from varying degrees of hearing loss, and this number is expected to reach nearly 2.5 billion by 2050 .
On April 23 , 2026 , Regeneron officially announced that the U.S. FDA had given accelerated approval to its investigational gene therapy Otarmeni ( lunsotogene parvec-cwha ), making it the first and currently only gene therapy approved for the treatment of hereditary hearing loss, and also Regeneron's first approved gene therapy .

The FDA emphasizes that this is the first therapy to directly address the molecular root causes of hereditary hearing loss. Scientifically, this represents a significant step forward in human medicine, moving from " symptom treatment " to " gene repair . " The success of Otarmeni not only validates the enormous potential of AAV vectors in auditory gene therapy but also reveals that achieving more efficient and precise delivery is key to next-generation research.
According to the press release, Otarmeni is the first gene therapy approved through the FDA Commissioner's National Priority Voucher Pilot Program ( CNPV ) and the second new molecular entity approved through CNPV . Regeneron will provide Otarmeni free of charge in the United States .
The newly approved Otarmeni is an adeno-associated virus (AAV) -based gene therapy that delivers a " normally functioning gene " to the patient's inner ear to replace a malfunctioning gene in the body. This therapy specifically targets a rare hearing impairment caused by mutations in the OTOF gene, which is responsible for producing key proteins necessary for sound signals to be transmitted to the brain. Therefore, the therapy aims to restore the ear 's ability to " hear , " rather than simply amplifying sound. The approval is based on the pivotal CHORD clinical trial (a phase I/II , multicenter, open-label study ) which enrolled 20 participants aged 10 months to 16 years.
Key clinical trial data showed that approximately 80% of patients experienced significant hearing improvement, with some even recovering to near-normal levels and being able to hear whispers. Children receiving treatment began responding to sounds within weeks and gradually became able to recognize language and participate in social interactions. Notably, some adolescent patients also experienced significant hearing improvement, suggesting that the treatment window may be wider than previously expected.
For patients' families, this signifies not only a medical breakthrough but also a life-changing event. While the medication itself is free, families may still need to bear the costs associated with surgery and medication administration. Regeneron stated that it hopes to eliminate " economic barriers " so that all eligible patients can equitably access this treatment. With the drug's approval, the company is actively collaborating with treatment centers to ensure patients can receive the medication within weeks.
Statistics show that approximately 50% of congenital hearing loss is related to genetic factors. Current clinical treatments primarily involve hearing aids or cochlear implants, but these methods do not address the root cause of hearing loss. Therefore, better alternative therapies are needed to treat hearing loss. With the rapid development of gene therapy, viral vector-based gene therapy has become a new and promising area for treating hereditary hearing loss.
In the domestic market, Heyuan Bio has already established a presence in this cutting-edge field, building a product and service system covering the entire process of auditory gene therapy. It is understood that Heyuan Bio can provide packaging services for dozens of AAV serotypes targeted for otological gene therapy, including AAV1-9 , Anc80L65 , AAV-PHP.eB , and AAV2.7m8 ; it can also provide various specific promoters targeting inner ear hair cells ( HCs , including inner hair cells, IHCs and outer hair cells, OHCs) , supporting cells (SCs) , and spiral ganglion neurons (SGNs) .

https://mp.weixin.qq.com/s/r2UcOMfddLy3aJSl_KQyHg